mother was born in Mexico City, and my father immigrated to Mexico City from Spain at the age of 17 in 1947. He was a selfmade man. Although not well educated, he worked hard, had a good work ethic, and consequently did quite well in Mexico. He died at the age of 66 from idiopathic pulmonary fi brosis. My mother, a wonderful lady, died at age 77 of lymphoma. Both were Catholics. We were raised as Catholics with strong conservative values.
I have a brother and two sisters. My older brother, Fernando, lives in Mexico. Initially, he was in the dress and textile industry, but 5 years ago he franchised four International House of Pancakes. My older sister, Rebecca, age 51, has Down syndrome. She works full-time at a McDonald's in Mexico, cleaning tables. She can read. She is somewhat independent even though she lives with my younger sister, Myriam, a housewife, with her son in Mexico City.
I went to Catholic primary and secondary school and entered medical school right out of high school-the National Autonomous University of Mexico in Mexico City. I went to medical school for 6 years. Th e fi fth year of my medical school was like an internship in the USA. I had a 1-year clinical rotation in Houston, spending a few months at Methodist and Hermann Hospitals and at some other hospitals in the area. Th at was an important year for me. It was the fi rst year I had lived independently, and it was the year that I met the person who became my wife. Karyn was born in Austin and raised in Houston. She was studying nursing and we were living next door to each other in the same dorm (Favrott Hall) in the middle of the Texas Medical Center. After that 1 year of training in Houston, I returned to Mexico to fi nish medical school (the sixth year) doing research in the pathology department at the best hospital in Mexico, the National Institute of Nutrition, and arguably one of the best hospitals in Latin America for internal medicine.
Roberts: How old were you then? Saucedo: I fi nished medical school at age 22, and the night before I was to interview for residency I was still trying to decide if I wanted to be a surgeon or an internist. I had interviews for both programs. I fi nally decided on internal medicine. I like to diagnose. I did my internal medicine training at the National Institute of Nutrition. Th e training was tremendous. I was very happy there. I worked over 110 hours per week in the wards. We only had a few hours to rest on Saturday evenings and Sunday afternoons and began at 5:00 am on Monday through Saturday. I was often called in the middle of the night for my 22 patients. Th ose years in internal medicine were crucial in my formation and were some of the most fulfi lling years of my career. I lived in the hospital taking care of patients day and night.
Roberts: When was that? Saucedo: From 1989 to 1992. I knew I wanted to be a cardiologist, and the best place in Mexico was the National Institute of Cardiology in Mexico City. It was founded 60 years ago as the fi rst heart institute in the world by Dr. Chavez. I did 3 years of cardiology training there. I wanted to become an interventional cardiologist, and to accomplish that goal meant coming to the USA for training. I got accepted to do interventional training at the Mayo Clinic and at the University of Michigan Ann Arbor. I decided to go to Michigan. I trained there for 2 years with Eric Bates, Mauro Moscucci, Steve Werns, and David Muller. After the fi rst year, I started getting a little antsy to go to another place that off ered the next level of complex interventions and clinical trials. I wrote Martin Leon at the Washington Hospital Center, Washington, DC, interviewed with him, and was accepted. I spent 1.5 years of formal training at the University of Michigan and then 1 year at the Washington Hospital Center.
Roberts: What year did you fi nish your training? Saucedo: June 1996. David Talley, chief of cardiology of the University of Arkansas for Medical Sciences, approached me at an American Heart Association meeting about 3 months before I was planning to return to Mexico. He off ered me the directorship of the catheterization lab at the Veterans Administration Hospital and at the University Hospital in Little Rock, Arkansas. I accepted and stayed almost 5 years (1997 until 2001) . I ran a busy research organization after Dr. Talley left. We had 15 to 20 research personnel doing a large number of clinical trials. In April 2002 I moved to the University of Oklahoma because of more opportunities, and I have been there since (9+ years).
Roberts: Do you still do percutaneous interventions?
Saucedo: I am the director of the cath lab. I spend 3 days a week in the cath lab and about 1.5 to 2 days a week in the clinic seeing patients. I am the medical director of the cath lab and the vice chief for the Division of Cardiology. Dwight Reynolds, the chief, is a device expert (defi brillators, pacemakers, etc.). Four years ago he was the president of the Heart Rhythm Society. I have a rather small research operation. About 80% of my time is devoted to seeing inpatients and working in the cath lab.
Roberts: You have done a lot of diff erent research involving the cath lab in the past 15 years. What are the investigative accomplishments that you are most proud of?
Saucedo: In Little Rock I led a large organization that allowed us to have a strong presence as trialists in the US. While in Little Rock with Robert Letterman, we published a report using angiogenesis for patients with claudication. We injected fi broblast growth factor directly into the common femoral arteries and showed it to be superior to placebo, permitting patients to walk longer with less pain. In collaboration with Dr. Eidt, we were the fi rst group to perform an endovascular repair of an abdominal aortic aneurysm. Also, we were fi rst in the state of Arkansas to have access to some of the newest stents, cath lab devices, antiplatelet drugs, and endografts. I also had a small platelet lab and did light transmission aggregometry, a technique I had learned at the University of Michigan working with Dr. Lucchesi of the Department of Pharmacology. In Little Rock I continued with light transmission aggregometry, looking at platelet function, and published a couple of papers on this subject. I started to work with the antiplatelet agent abciximab, an intravenous glycoprotein 2b/3a antagonist.
Roberts: What has happened to fi broblast growth factor? Saucedo: Th e problem with most angiogenesis trials is that most have a very strong placebo eff ect. Follow-up studies have not been as positive as initial studies. We are doing a few trials on patients with claudication and also those with critical limb ischemia. We hope at some point that there will be a drug, injected intramuscularly, intravenously, or interarterially, that will help produce collaterals to improve outcomes.
Roberts: I presume that you are now in the midst of trials on antiplatelet and antithrombotic agents? Which drugs are going to win?
Saucedo: For about 14 years we only had two oral antiplatelet agents, other than aspirin, that were approved by the Food and Drug Administration: ticlopidine and clopidogrel. We used clopidogrel as the preferred second oral antiplatelet agent available after aspirin. Two years ago, prasugrel was approved in the US, mainly on the basis of data from the TRITON and TIMI 38 trials. Th is study showed that in both ST-elevation and non-ST-elevation patients having coronary angioplasty, prasugrel was associated with about a 20% relative risk reduction of death, myocardial infarction, and stroke. Th ere was more bleeding with prasugrel than with clopidogrel. Th at is one of my passions: getting to that "sweet spot" where there is a perfect balance between reducing myocardial ischemic complications without increasing bleeding risk. Prasugrel is metabolized easier than clopidogrel. Th e active metabolite of both drugs is similar, but because of the easier metabolism of prasugrel, it is a more active drug. Prasugrel inhibits platelets more rapidly and more intensely than clopidogrel. Th ere is also less variability of its antiplatelet eff ect compared with clopidogrel.
Th e newest oral antiplatelet agent approved in the US is ticagrelor. Th is drug is not a thienopyridine like prasugrel and clopidogrel. It acts on the same receptor within the platelet, which is P2Y12, also known as the ADP receptor. Th is drug was tested in the PLATO trial and compared with clopidogrel. Compared with clopidogrel, ticagrelor reduced myocardial ischemic events, including death, when given to patients presenting with acute coronary syndromes. Th ere is another receptor in the platelets called the "thrombin" receptor or the proteinase-activated receptor (PAR-1), which is activated through thrombin. Investigational drugs such as vorapaxar block the eff ect of thrombin, thus preventing the platelet from being activated by thrombin. Th e major clinical trial, TRACER, published in November 2011 in the New England Journal of Medicine showed a minimal effi cacy improvement but a signifi cant increased risk of bleeding complications, including intracranial hemorrhage.
Roberts: Which antiplatelet agent are you using now? a major cardiovascular event in the next 10 years. I have a 98% chance in the next 10 years that I will not have an event, and taking a statin would reduce that to 99%, but there is a cost to it. 
